Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06959121 · ClinicalTrials.gov registry record · NA
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
A NA study of Atrial Fibrillation and Ablation, sponsored by Pulse Biosciences.
- Recruiting
- Registry status
- NA
- Development phase
- 135
- Enrollment target
- 2
- Study locations
NCT06959121: Recruiting NA study of Atrial Fibrillation and Ablation, sponsored by Pulse Biosciences.
NCT06959121 is a NA study of Atrial Fibrillation and Ablation that is actively recruiting participants, run by Pulse Biosciences. The registered enrollment target is 135 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06959121, a NA study of Atrial Fibrillation and Ablation, is actively recruiting participants, sponsored by Pulse Biosciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 135 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.
Primary Outcome
Freedom from AF/AFL/AT of 30 seconds or greater duration and freedom for use of new or increased dose of previously failed Class I or III antiarrhythmic drugs (AADs) prescribed to treat atrial arrhythmias.
Conditions Studied
Interventions
- DEVICE CellFX® nsPFA™ Cardiac Surgery System
Study Locations (2)
California
- Adventist Heart Institute: Adventist Health St. Helena - St. Helena
Michigan
- Cardiac Surgery Clinic | Frankel Cardiovascular Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT06959121 shows while recruiting
NCT06959121 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which CellFX® nsPFA™ Cardiac Surgery System is the first listed.
NCT06959121 reports a single indexed study location in California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06959121 about?
NCT06959121 is a clinical study titled "CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation". The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.
What is the current status of trial NCT06959121?
This trial is currently recruiting. It is a NA study. The enrollment target is 135 participants. The study started on 2025-10-23. Estimated completion is 2028-12.
What conditions does trial NCT06959121 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Ablation, Maze Procedure, AF.
What interventions are being tested in trial NCT06959121?
The interventions under investigation include: CellFX® nsPFA™ Cardiac Surgery System (DEVICE).
Who is sponsoring clinical trial NCT06959121?
This trial is sponsored by Pulse Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06959121 being conducted?
This trial has 2 study locations across California, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06959121's enrollment target sits among peer trials
135 126th of 202 higher than 77 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
The CONFORM Pivotal Trial
RECRUITING · NA
-
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
-
Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI